Free Access
Issue
Med Sci (Paris)
Volume 27, Number 6-7, Juin–Juillet 2011
Page(s) 662 - 666
Section Forum
DOI https://doi.org/10.1051/medsci/2011276020
Published online 01 July 2011
  1. Cassier M, Stoppa-Lyonnet D. L’opposition contre les brevets de Myriad Genetics et leur révocation totale ou partielle en Europe : premiers enseignements. Med Sci (Paris) 2005 ; 21 : 658-662. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Wadman M. Testing time for gene patents as Europe rebels. Nature 2001 ; 413; 443. [CrossRef] [PubMed] [Google Scholar]
  3. Cassier M. Relations entre secteurs public et privé dans la recherche sur le génome. Med Sci (Paris) 2000 ; 16 : 26-30. [Google Scholar]
  4. Gad S, Stoppa-Lyonnet D, Aurias A, Bensimon A. « Peignage d’ADN » et grands réarrangements du gène brca1 ou comment dénoncer le monopole de Myriad Genetics sur les tests de prédisposition au cancer du sein. Med Sci (Paris) 2001 ; 17 : 1072-1075. [Google Scholar]
  5. VanOverwalle G. Turning patent swords into shares. Science 2010 ; 330 : 1630-1631. [CrossRef] [PubMed] [Google Scholar]
  6. Heller MA, Eisenberg RS. Can patents deter innovation? The anticommons in biomedical research. Science 1998 ; 280 : 698-701. [CrossRef] [PubMed] [Google Scholar]
  7. PK. Yu SARS and the patent race : an introduction to the patent law, social policy, and public interest. , Symposium, Michigan State University-DCL Public Law and Legal Theory Working Paper Series, n°01-17, 2003. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.